BPC-157 for Sports Injuries: The Preclinical Evidence
Peptides in Sports Medicine
35 preclinical studies
A 2025 systematic review found 35 animal studies and only 1 clinical study of BPC-157 for orthopaedic sports injuries.
Vasireddi et al., HSS Journal, 2025
Vasireddi et al., HSS Journal, 2025
View as imageBPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in human gastric juice that has been studied for musculoskeletal healing in animal models since the late 1990s. The preclinical literature spans tendon transection, muscle crush and transection, ligament rupture, and segmental bone defects, with consistently positive results across tissue types. For a broader look at how this peptide fits into the sports medicine landscape, see Peptides in Sports Medicine: What Legitimate Research Supports.
A 2025 systematic review by Vasireddi et al. in HSS Journal identified 36 total studies on BPC-157 for orthopaedic applications: 35 preclinical and 1 clinical.[1] McGuire et al. (2025) published a separate narrative review titled "Regeneration or Risk?" confirming the consistency of animal data while emphasizing the near-total absence of human evidence.[2] Matek et al. (2026) published the most comprehensive review to date, covering tendon, ligament, and muscle injury models alongside myotendinous and osteotendinous junction repair.[3]
This article examines the preclinical evidence by tissue type, covering every major musculoskeletal category: tendon, muscle, ligament, and bone. The goal is precision about what has been demonstrated in animals and honesty about where that evidence stops. For each tissue type, the specific models, findings, and limitations are evaluated individually rather than aggregated into a single verdict.
Key Takeaways
- BPC-157 accelerated Achilles tendon healing in rats with improved biomechanical strength and earlier functional recovery after complete transection (Staresinic et al., 2003)
- In transected rat quadriceps, BPC-157 restored muscle function and increased load-to-failure measurements compared to controls (Staresinic et al., 2006)
- BPC-157 improved ligament healing in rats, reducing joint instability and restoring biomechanical properties after medial collateral ligament transection (Cerovecki et al., 2010)
- A single rat study showed BPC-157 promoted segmental bone defect healing comparable to autologous bone graft (Sebecic et al., 1999)
- The peptide upregulated growth hormone receptor expression in tendon fibroblasts and activated VEGFR2-Akt-eNOS angiogenic signaling (Chang et al., 2014; Seiwerth et al., 2018)
- As of 2026, no randomized controlled trial has tested BPC-157 for any sports injury in humans
Tendon Healing: The Strongest Evidence Base
Tendon injuries represent the most studied application for BPC-157 in sports medicine contexts, with at least eight preclinical studies examining different tendon models.
Staresinic et al. (2003) performed complete Achilles tendon transection in rats and administered BPC-157 either locally or systemically. Both routes of administration accelerated healing: treated animals showed earlier functional recovery and superior biomechanical properties (higher load to failure, greater stiffness) at the repair site compared to saline controls.[4] This study established the foundational evidence that BPC-157 could affect tendon repair in a surgically relevant model.
Krivic et al. (2006) extended this work to Achilles detachment from bone, a more complex injury involving the osteotendinous junction. BPC-157 promoted tendon-to-bone healing with improved attachment strength.[5] This is particularly relevant to sports medicine because avulsion injuries (where tendons pull away from bone) are common in explosive athletic movements.
Chang et al. (2011) investigated the mechanism behind BPC-157's tendon effects and found that the peptide promoted tendon outgrowth, cell survival, and migration in cell culture models. Treated tendon explants showed greater outgrowth distance and higher fibroblast viability.[6]
The mechanistic link was further clarified by Chang et al. (2014), who demonstrated that BPC-157 upregulated growth hormone receptor (GHR) expression in tendon fibroblasts. This finding is significant because GHR signaling is a known driver of tendon repair, and it suggests BPC-157 may amplify the body's existing healing pathways rather than activating entirely novel ones.[7]
Collectively, the tendon data shows a consistent pattern: BPC-157 enhances multiple aspects of tendon repair in rats, from cellular outgrowth to biomechanical restoration. The breadth of tendon models tested (transection, detachment, outgrowth) strengthens the case that the effect is real in rats rather than an artifact of a single experimental setup.
The limitation across all tendon studies is the model organism. Rat Achilles tendons are structurally simpler than human tendons, with different collagen cross-linking patterns, faster baseline turnover, and distinct mechanical loading profiles. Rats bear weight on four limbs and have lower peak tendon stresses. Complete tendon transection in a rat is also a more severe and more uniform injury than the partial tears and tendinopathies that constitute most sports injuries. A recreational runner with patellar tendinopathy faces a fundamentally different biological environment than a rat with a surgically divided Achilles tendon.
Muscle Injury: Crush, Transection, and Corticosteroid Impairment
BPC-157's effects on skeletal muscle injury have been studied in several models that are relevant to contact sports and overuse injuries.
Novinscak et al. (2008) demonstrated that BPC-157 improved recovery from gastrocnemius muscle crush injury in rats, a model that simulates blunt-force muscle trauma. Treated animals showed faster functional restoration and reduced inflammatory markers compared to controls.[8]
Staresinic et al. (2006) tested BPC-157 in complete quadriceps transection, a model of severe muscle disruption. Treatment improved muscle diameter, myofibril organization, and load-to-failure measurements, indicating both structural and functional recovery benefits.[9]
A particularly relevant finding for athletes came from Pevec et al. (2010), who examined BPC-157's effects on muscle healing impaired by systemic corticosteroid administration. Corticosteroids are commonly used by athletes for inflammation management but are known to delay tissue healing. BPC-157 counteracted the corticosteroid-induced healing impairment, restoring muscle recovery to levels comparable to non-corticosteroid-treated controls.[10] If this finding translates to humans, it would have direct implications for athletes who use corticosteroid injections alongside rehabilitation.
Japjec et al. (2021) studied BPC-157 at the myotendinous junction, the transition zone between muscle and tendon that is a frequent site of strain injuries in sprinters and soccer players. BPC-157 improved healing of disabled myotendinous junctions in rats, enhancing the integrity of this vulnerable interface.[11]
Ligament Healing
Cerovecki et al. (2010) transected the medial collateral ligament (MCL) in rats and treated them with BPC-157. The peptide improved ligament healing biomechanics, reduced post-injury joint instability, and produced better histological outcomes at the repair site. Treated ligaments showed more organized collagen fiber alignment and greater tensile strength.[12]
MCL injuries are common across multiple sports (skiing, soccer, combat sports), making this a clinically relevant model. The finding that BPC-157 improved both the structural quality and the mechanical properties of the healing ligament goes beyond simple acceleration of healing, suggesting qualitative improvement in the repair tissue itself.
The ligament evidence base is thinner than the tendon data. Only one primary study (Cerovecki et al., 2010) directly examined ligament transection. Other studies reference ligament healing in the context of broader reviews, but the direct experimental evidence rests on a single study from a single laboratory. No anterior cruciate ligament (ACL) model, the most consequential sports ligament injury, has been tested with BPC-157.
Bone Healing
The bone healing evidence for BPC-157 is thinner than the tendon and muscle data but includes one significant early study. Sebecic et al. (1999) created segmental bone defects in rabbit radii and compared BPC-157 treatment to autologous bone graft (the clinical gold standard) and bone marrow injection. BPC-157 promoted callous mineralization and resolution of the bone defect with predominantly lamellar bone formation rather than fibrous scar tissue, performing comparably to autologous bone graft.[13]
This result has not been replicated or extended in subsequent fracture models, which limits its weight. A single study in rabbits (not rats) using a segmental defect model (not a typical fracture pattern) provides a preliminary signal that BPC-157 may affect bone biology, but the evidence base is far too thin for conclusions about stress fractures or other sports-related bone injuries.
Mechanisms: How BPC-157 May Promote Healing
The proposed mechanism of BPC-157 centers on two interconnected pathways.
Angiogenesis. Brcic et al. (2009) demonstrated that BPC-157 modulated angiogenesis in both muscle and tendon healing models, increasing new blood vessel formation at injury sites.[14] Seiwerth et al. (2018) reviewed BPC-157's relationship with standard angiogenic growth factors and identified activation of the VEGFR2-Akt-eNOS signaling cascade, which promotes nitric oxide production and endothelial cell proliferation. The peptide also influenced VEGF, FGF, and EGF expression at wound sites.[15]
Nitric oxide modulation. BPC-157 appears to interact with nitric oxide (NO) pathways in a context-dependent manner: promoting NO synthesis where it aids healing while counteracting excess NO in conditions where it causes tissue damage. This bidirectional modulation has been documented across multiple organ systems and injury types.
Growth factor receptor upregulation. Chang et al. (2014) showed that BPC-157 increased growth hormone receptor expression in tendon fibroblasts, potentially amplifying the effects of endogenous growth hormone on tissue repair.[7]
These mechanisms are biologically plausible and have been demonstrated in vitro and in vivo in animal models. The angiogenic and NO-modulating effects are consistent with the observed healing acceleration across tissue types: tendon, muscle, ligament, and bone all depend on adequate blood supply for repair, and all benefit from controlled inflammatory modulation during the healing cascade.
The critical unknown is whether the same pathways are activated at clinically relevant doses in human tissues following subcutaneous or intramuscular injection, the routes most commonly used by athletes. Peptide bioavailability, tissue distribution, and receptor density differ between rats and humans, and the effective dose in a 250-gram rat does not scale linearly to a 90-kilogram athlete.
What the Evidence Does Not Show
The preclinical literature on BPC-157 for sports injuries has consistent positive results, but several limitations constrain interpretation:
No human sports injury data. The Vasireddi et al. (2025) systematic review found zero randomized controlled trials and only one uncontrolled clinical study (Lee et al., 2021, examining knee pain in 16 patients).[1]
Almost exclusively from one research group. The majority of BPC-157 musculoskeletal studies originate from Sikiric's laboratory at the University of Zagreb. Independent replication from other institutions is limited. This is not evidence of fraud, but single-laboratory findings carry less weight than multi-center replications.
Acute, surgically created injuries only. All tendon and ligament studies used complete transection models. Sports injuries are typically partial tears, chronic tendinopathies, or strain injuries that involve different cellular environments and healing trajectories. Whether BPC-157 helps a partial rotator cuff tear in the same way it helps a completely transected rat Achilles tendon is unknown.
Dose and route uncertainties. Preclinical studies used a range of doses (typically 10 mcg/kg in rats) and administration routes (local injection at the injury site, systemic intraperitoneal injection, oral administration in drinking water). Effective local and systemic doses have not been established for human musculoskeletal applications, and the doses used by athletes are based on extrapolation and community consensus rather than pharmacokinetic data.
No long-term safety data. The pro-angiogenic mechanism that may help healing could theoretically promote tumor vascularization with chronic use. This concern has not been investigated in long-term animal studies. Athletes using BPC-157 cyclically over months or years for injury management are operating outside the bounds of any published safety assessment. For the broader context on BPC-157's evidence base, see BPC-157 and Athletes: From Joe Rogan to a 12-Year-Old's Parents. For those interested in how the injury prevention narrative differs between BPC-157 and TB-500, see BPC-157 and TB-500 in Bodybuilding: The Injury Prevention Narrative. Athletes evaluating collagen supplementation as a more conservative alternative should see Collagen Peptides for Athletes: Tendon, Ligament, and Joint Evidence.
Mayfield et al. (2026) published a primer for orthopaedic and sports medicine physicians on injectable peptide therapy, acknowledging the growing clinical interest while cautioning that the evidence does not yet support evidence-based use outside of clinical trials.[16]
The Bottom Line
BPC-157 has the most consistent preclinical evidence of any peptide for musculoskeletal healing, spanning tendon, muscle, ligament, and bone models across more than 35 animal studies. The mechanisms center on angiogenesis via VEGFR2-Akt-eNOS signaling, nitric oxide modulation, and growth hormone receptor upregulation. The evidence stops at the species barrier: zero randomized human trials exist for any sports injury application. The predominantly single-laboratory origin, exclusive use of acute surgical injury models, and absence of chronic-use safety data mean that the preclinical promise has not been tested under conditions that reflect actual sports injuries in human athletes.